Mitomycins
- Generic Name
- Mitomycins
- Brand Names
- Jelmyto, Mitosol, Mutamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C15H18N4O5
- CAS Number
- 50-07-7
- Unique Ingredient Identifier
- 50SG953SK6
- Background
Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of Streptomyces caespitosus. It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discov...
- Indication
For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery. Mitomycin is also indicated as a pyelocalyceal solution for the treatment of adults with low-grade upper tract urothelial cancer (LG-UTUC).
- Associated Conditions
- Anal Cancer, Bladder Cancer, Breast Cancer, Carcinoma of the Head and Neck, Cervical Cancer, Gastric Adenocarcinoma, Mesothelioma, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Adenocarcinoma, Ab externo surgery Glaucoma, Low-grade Upper Tract Urothelial Cancer (LG-UTUC)
- Associated Therapies
- -
Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT02092298
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Investigating Bladder Chemotherapy Instead of Surgery for Low Risk Bladder Cancer
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 82
- Registration Number
- NCT02070120
- Locations
- 🇬🇧
James Cook University Hospital, Middlesbrough, Cleveland, United Kingdom
🇬🇧Macclesfield District General Hospital, Macclesfield, Cheshire, United Kingdom
🇬🇧Derriford Hospital, Plymouth, Devon, United Kingdom
HIPEC for Peritoneal Carcinomatosis
- Conditions
- Interventions
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Albert Einstein College of Medicine
- Target Recruit Count
- 51
- Registration Number
- NCT02040142
- Locations
- 🇺🇸
Department of Surgery, Montefiore Medical Center- Weiler Division, Bronx, New York, United States
The Use of MMC During PRK and Its Effect on Postoperative Topical Steroid Requirements
- Conditions
- Interventions
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- United States Naval Medical Center, San Diego
- Target Recruit Count
- 300
- Registration Number
- NCT02030990
- Locations
- 🇺🇸
Navy Warfighter Refractive Surgery Center, San Diego, California, United States
The Effect of Sponge Versus No-Sponge Placement of Mitomycin-C on the Outcomes of Trabeculectomy With Ex-PRESS Glaucoma Filtration Device
- Conditions
- Interventions
- First Posted Date
- 2013-12-20
- Last Posted Date
- 2018-02-09
- Lead Sponsor
- Duke University
- Target Recruit Count
- 100
- Registration Number
- NCT02016898
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Seoul National University Hospital
- Registration Number
- NCT01953406
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal.
- Conditions
- Interventions
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Instituto do Cancer do Estado de São Paulo
- Target Recruit Count
- 51
- Registration Number
- NCT01941966
- Locations
- 🇧🇷
ICESP, Sao Paulo, SP, Brazil
Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT01858025
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Roberts Proton Therapy Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal
- Conditions
- Interventions
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2016-05-19
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Target Recruit Count
- 8
- Registration Number
- NCT01843452
- Locations
- 🇨🇭
Inselspital, Bern, Switzerland
🇨🇭Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇨🇭Hôpitaux Universitaires de Genève (HUG), Geneva, Switzerland
Function and Modulation of Fibulin-1 Assembly in Nucleus of Corneal Fibroblasts
- Conditions
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Far Eastern Memorial Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT01808495
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.